牛牛AI助理已提取核心訊息
On February 14, 2024, AbbVie Inc. announced a significant leadership transition with Robert A. Michael set to succeed Richard A. Gonzalez as Chief Executive Officer (CEO), effective July 1, 2024. Gonzalez, who has been at the helm since AbbVie's inception in 2013, will retire from his CEO role and take on the position of Executive Chairman of the Board. Michael, currently serving as AbbVie's President and Chief Operating Officer, has a long history with the company, having held various leadership roles since joining Abbott in 1993, which later became part of AbbVie. The Board of Directors has also appointed Michael as a Class II director on the Board, coinciding with his CEO appointment. The announcement was made through a press release issued on February...Show More
On February 14, 2024, AbbVie Inc. announced a significant leadership transition with Robert A. Michael set to succeed Richard A. Gonzalez as Chief Executive Officer (CEO), effective July 1, 2024. Gonzalez, who has been at the helm since AbbVie's inception in 2013, will retire from his CEO role and take on the position of Executive Chairman of the Board. Michael, currently serving as AbbVie's President and Chief Operating Officer, has a long history with the company, having held various leadership roles since joining Abbott in 1993, which later became part of AbbVie. The Board of Directors has also appointed Michael as a Class II director on the Board, coinciding with his CEO appointment. The announcement was made through a press release issued on February 20, 2024, and is part of a planned succession to ensure a smooth transition of leadership. The company's press release highlighted Michael's significant contributions to AbbVie, including his involvement in key business development opportunities and navigating the end of exclusivity for Humira in the U.S. Gonzalez's tenure as CEO saw the company's market capitalization increase substantially, and he will continue to offer his experience as Executive Chairman.
2024年2月14日，艾伯維公司宣佈了重大的領導層交接，羅伯特·邁克爾將接替理查德·岡薩雷斯擔任首席執行官（CEO），自2024年7月1日起生效。岡薩雷斯自2013年艾伯維成立以來一直掌舵，他將從首席執行官一職退休，擔任董事會執行主席一職。邁克爾目前擔任艾伯維總裁兼首席運營官，在公司有着悠久的歷史，自1993年加入雅培以來，他曾擔任過各種領導職務，雅培後來成爲艾伯維的一員。董事會還任命Michael爲董事會二類董事，恰逢其首席執行官的任命。該公告是通過2024年2月20日發佈的新聞稿宣佈的，是爲確保領導層平穩過渡而計劃繼任的一部分。該公司的新聞稿強調了邁克爾對艾伯維的重大貢獻，包括他參與關鍵業務發展機會以及爲Humira在美國的獨家經營權的終結做好準備。岡薩雷斯在擔任首席執行官期間，公司的市值大幅增加，他將繼續提供擔任執行董事長的經驗。
2024年2月14日，艾伯維公司宣佈了重大的領導層交接，羅伯特·邁克爾將接替理查德·岡薩雷斯擔任首席執行官（CEO），自2024年7月1日起生效。岡薩雷斯自2013年艾伯維成立以來一直掌舵，他將從首席執行官一職退休，擔任董事會執行主席一職。邁克爾目前擔任艾伯維總裁兼首席運營官，在公司有着悠久的歷史，自1993年加入雅培以來，他曾擔任過各種領導職務，雅培後來成爲艾伯維的一員。董事會還任命Michael爲董事會二類董事，恰逢其首席執行官的任命。該公告是通過2024年2月20日發佈的新聞稿宣佈的，是爲確保領導層平穩過渡而計劃繼任的一部分。該公司的新聞稿強調了邁克爾對艾伯維的重大貢獻，包括他參與關鍵業務發展機會以及爲Humira在美國的獨家經營權的終結做好準備。岡薩雷斯在擔任首席執行官期間，公司的市值大幅增加，他將繼續提供擔任執行董事長的經驗。
有用
沒用